You are here

Samumed Announces Sponsorship of Knee Osteoarthritis Registry Study

Collaboration will prospectively evaluate the natural history of knee osteoarthritis progression

SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today its sponsorship of a registry study in collaboration with investigators at Brigham and Women’s Hospital in Boston. The study will focus on the evaluation of data collected from 100 knee osteoarthritis (OA) patients.

The study, called the Osteoarthritis Registry of Biomarker and Imaging Trajectories, or ORBIT, will recruit patients from Brigham and Women’s Hospital. In addition to capturing records of imaging and biospecimen data, ORBIT will collect patient-reported symptoms information and functional performance measures. The study will utilize this deidentified data source to better understand the natural history of knee OA, as well as patients’ responses to specific treatments.

Jeymi Tambiah, MBChB, Senior Vice President, Medical Affairs of Samumed, commented, “ORBIT will help OA researchers better understand how this debilitating disease progresses in patients, as part of efforts to improve approaches to treating the condition. We are pleased to be collaborating with a prestigious institution such as Brigham and Women’s Hospital, and we look forward to the study outcomes.”

About Samumed
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Learn more about Samumed’s potential regenerative drug candidates and broad clinical pipeline at

Brigham and Women’s Hospital Contact:
Jeffrey N. Katz, MD, MSc
Brigham and Women’s Hospital, Boston

Samumed Corporate Contact:
Erich Horsley
Samumed, LLC

Samumed Investor Contact:
Ashley Robinson
LifeSci Advisors

Samumed Media Contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations

Monday, October 15, 2018 - 08:00